Dr. Neal Shore on Increasing Healthcare Costs and Metastasis Risk in Prostate Cancer
August 7th 2016Neal Shore, MD, medical director of the Carolina Urologic Research Institute, discusses a retrospective study investigating the relationship between treatment costs and the timing of diagnosis of metastases in prostate cancer.
Gyorgy Petrovics on Frequency of BRCA Mutations in African American Prostate Cancer Patients
August 2nd 2016Gyorgy Petrovics, PhD, associate director, Center for Prostate Disease Research (CPDR), research associate professor in the department of surgery at the Uniformed Services University of the Health Sciences (USUHS), discusses BRCA1 and BRCA2 mutations in African American prostate cancer patients.
Dr. Rastinehad on Transperineal Fusion Biopsy for Prostate Cancer Focal Therapy
June 3rd 2016Art Rastinehad, DO, Director of Focal Therapy and Interventional Urologic Oncology, Mount Sinai Health System, discusses an electromagnetically (EM) tracked transperineal MR/US fusion-guided biopsy platform (tpFBx) for prostate cancer.
Gene Expression Signature Predicts Hormonal Resistance in Prostate Cancer
May 24th 2016Using the Decipher Prostate Cancer Classifier assay to predict which patients might respond to hormonal therapy has resulted in the discovery and validation of an adjuvant androgen-deprivation therapy resistance signature.
Dr. Jim Hu on Reevaluating PSA and the PLCO Trial
May 19th 2016Jim Hu, MD, MPH, director of the LeFrak Center for Robotic Surgery at NewYork-Presbyterian/Weill Cornell Medical Center and the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College, discusses critical flaws in the landmark PLCO trial in prostate cancer.
PD-1 Expression on Monocytes Potential Immunotherapy Biomarker in RCC
May 13th 2016Mohammed Haseebuddin, MD, discusses results of a study which demonstrated that elevated preoperative classical monocyte PD-1 mean fluorescence intensity level and lower CM was linked to poor survival in patients with clear cell renal cell carcinoma, as well as the challenges with using PD-1 as a biomarker in these patients.
HIFU Demonstrates Significant Role in Prostate Cancer
Results of a multi-institutional prospective study showed that treatment with unilateral high-intensity focused ultrasound led to eradication of all clinically significant cancer in the treated lobe for 94% of patients with early prostate cancer.
Radium-223/Abiraterone Combo Improves QOL, Bone Pain in mCRPC
The combination of radium-223 dichloride (Xofigo) and abiraterone acetate (Zytiga) was associated with significant reductions in bone pain, as well as improvements in quality of life, in patients with metastatic castration-resistant prostate cancer.
Krishna Vanaja Donkena on Using Immune Markers to Predict Survival in Bladder Cancer
May 12th 2016Krishna Vanaja Donkena, PhD, Assistant Professor of Biochemistry and Molecular Biology, Center for Individualized Medicine, Mayo Clinic, discusses using immune and checkpoint markers to predict cancer-specific survival in bladder cancer.
Task Force PSA Recommendation Challenged Following Analysis
Major health policy implications follow findings from the landmark Prostate, Lung, Colorectal, and Ovary screening trial, after it was found that 80% of the control group reported at least one PSA test during the trial.
Liquid Imiquimod Formulation May Induce Immune Response in Bladder Cancer
TMX-101 (Vesimune), a liquid formulation of the toll-like receptor 7 agonist imiquimod, appeared safe and demonstrated preliminary clinical activity, including the potential to induce an immune response, in patients with non-muscle invasive bladder cancer.
Molecular Testing, New Biomarkers on Horizon for Immunotherapy in RCC
May 11th 2016Mark Ball, MD, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti–PD-1 therapy in renal cell carcinoma, the future of immunotherapy, and what significance genomic testing may hold.
Lower CV Event Rate With Degarelix Versus LHRH Agonist Irrespective of Baseline Risk
Prostate cancer patients with different baseline cardiovascular risk had similar reductions in cardiovascular event rates when treated with the LHRH antagonist degarelix versus an LHRH agonist.